



Zedira communication

Zedira presents preclinical data at "14th International Coeliac Disease Symposium 2011" in Oslo

The poster presentation entitled "preclinical development of tissue transglutaminase blockers" is available for <u>download</u>.

ZED-101 is a peptidomimetic blocker targeting TG2 intended for the development of a non dietary therapy for celiac disease.

For more details about the conference we refer to <u>14th International Coeliac Disease</u> <u>Symposium 2011</u>.

This communication is published by:

Zedira GmbH

Roesslerstr. 83 64293 Darmstadt Germany

Phone: +49 6151 3251-00 Fax: +49 6151 3251-19

Web: www.zedira.com E-Mail: contact@zedira.com

© 2011, Zedira GmbH